US FDA On Resuming Normal Manufacturing Operations When Pandemic Recedes
Executive Summary
Focus on restarting production, easing drug shortages and completing quality assurance activities for quarantined batches, agency guidance says.
You may also be interested in...
The Steps Drug Makers Must Take Now To Avoid A Post-COVID-19 Manufacturing Crisis
How pharmaceutical companies should plan to catch up after the pandemic and explain what happened to inspectors.
US FDA issues new guideline on emergency plans
The US Food and Drug Administration has issued final guidance aimed at encouraging manufacturers of so-called "medically necessary drug products" and their raw materials and components to develop contingency production plans for use during emergencies that result in high absenteeism at production facilities.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.